ENTRADA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.45 USD | +0.73% |
|
+2.47% | -17.50% |
| Sales 2024 * | 61.91M 4.96B | Sales 2025 * | 28.63M 2.29B | Capitalization | 403M 32.33B |
|---|---|---|---|---|---|
| Net income 2024 * | -81M -6.49B | Net income 2025 * | -139M -11.14B | EV / Sales 2024 * | 5.15 x |
| Net cash position 2024 * | 84.48M 6.77B | Net cash position 2025 * | 110M 8.77B | EV / Sales 2025 * | 10.3 x |
| P/E ratio 2024 * |
-5.44
x | P/E ratio 2025 * |
-3.79
x | Employees | 159 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.21% |
More Fundamentals
* Assessed data
More news
Latest transcript on Entrada Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +0.73% | ||
| 1 week | +2.47% | ||
| Current month | -12.14% | ||
| 1 month | -13.24% | ||
| 3 months | -16.05% | ||
| 6 months | -14.14% | ||
| Current year | -17.50% |
1 week
11.91
14.03
1 month
11.8114.38
Current year
11.3517.26
1 year
10.6218.44
3 years
5.1236.85
5 years
5.1236.85
10 years
5.1236.85
| Managers | Title | Age | Since |
|---|---|---|---|
Dipal Doshi
CEO | Chief Executive Officer | 48 | 31/07/17 |
Kory Wentworth
DFI | Director of Finance/CFO | 45 | 31/10/20 |
Nathan Dowden
PSD | President | 54 | 03/11/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Kim
BRD | Director/Board Member | 65 | 30/11/20 |
Mary Thistle
BRD | Director/Board Member | 64 | 03/05/21 |
Gina Chapman
BRD | Director/Board Member | 57 | 31/08/23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 12.45 | +0.73% | 25,818 |
| 25/04/24 | 12.36 | -0.56% | 84,124 |
| 24/04/24 | 12.43 | -3.57% | 38,559 |
| 23/04/24 | 12.89 | -1.60% | 43,975 |
| 22/04/24 | 13.1 | +7.82% | 119,085 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Companyâs Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
12.45
USD
Average target price
21
USD
Spread / Average Target
+68.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.50% | 403M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- TRDA Stock
